Compare Ascendis Pharma A/S (ASND) vs Ross Stores, Inc. (ROST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Ross Stores, Inc. — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while Ross Stores, Inc. trades at $222 (market cap $71.50B). The key difference: Ross Stores, Inc. is far larger — about 4× Ascendis Pharma A/S's market cap, and Ross Stores, Inc. pays a 0.8% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | ROST | |
|---|---|---|
Market Cap | $17.74B | $71.50B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $240.13 |
52-Week Low | $163.32 | $127.59 |
Enterprise Value | $18.11B | $72.09B |
Dividend Yield | — | 0.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Ross Stores (ROST) trades at $222.88, up 1.02% with strong momentum near recent highs. The stock shows bullish technical signals with consistent earnings beats in recent quarters (Q3 2025-Q1 2026) and robust fundamentals including 38.98% ROE and 9.74% net margin. Revenue growth accelerated to $21.13B in 2025, with analyst consensus strongly favoring Buy ratings (63.83%) and a $259 price target representing 16% upside potential.
Outlook remains positive given strong operational execution and consumer demand, though valuation multiples (P/E 31.13) appear elevated. Key risks include retail sector competition and economic sensitivity. Institutional sentiment supports further gains if earnings momentum continues through Q2 2026 results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →
